106 related articles for article (PubMed ID: 16224407)
1. Minimal residual disease: current status in leukemia.
Stock W
Clin Adv Hematol Oncol; 2003 Apr; 1(4):210-1. PubMed ID: 16224407
[No Abstract] [Full Text] [Related]
2. [Childhood acute leukemia: current status and future perspectives in MRD-based therapy].
Tsurusawa M
Rinsho Ketsueki; 2005 Feb; 46(2):109-20. PubMed ID: 16447704
[No Abstract] [Full Text] [Related]
3. Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept?
Paietta E
Bone Marrow Transplant; 2002 Mar; 29(6):459-65. PubMed ID: 11960263
[TBL] [Abstract][Full Text] [Related]
4. [Detection of minimal residual disease in leukemia using flow cytometry].
Muroi K
Rinsho Ketsueki; 2008 Jun; 49(6):397-407. PubMed ID: 18646607
[No Abstract] [Full Text] [Related]
5. What do we mean by sensitivity when we talk about detecting minimal residual disease?
Steinbach D; Debatin KM
Leukemia; 2008 Aug; 22(8):1638-9. PubMed ID: 18305558
[No Abstract] [Full Text] [Related]
6. Minimal residual disease testing of acute leukemia by flow cytometry immunophenotyping: a retrospective comparison of detection rates with flow cytometry DNA ploidy or FISH-based methods.
Zwick D; Cooley L; Hetherington M
Lab Hematol; 2006; 12(2):75-81. PubMed ID: 16751134
[TBL] [Abstract][Full Text] [Related]
7. Benefits of minimal residual disease negativity in the therapy of chronic lymphocytic leukemia.
Kay NE
Clin Adv Hematol Oncol; 2008 Oct; 6(10):727-9. PubMed ID: 18997661
[No Abstract] [Full Text] [Related]
8. Acute lymphoblastic leukemia: diagnosis and detection of minimal residual disease following therapy.
Digiuseppe JA
Clin Lab Med; 2007 Sep; 27(3):533-49, vi. PubMed ID: 17658406
[TBL] [Abstract][Full Text] [Related]
9. [Modern leukemia diagnosis in adults].
Heilmeier B; Spiekermann K; Bohlander S; Buske C; Feuring-Buske M; Schneider S; Hiddemann W; Braess J
Dtsch Med Wochenschr; 2009 Jun; 134(23):1222-6. PubMed ID: 19472094
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease, the rationale for adjuvant therapy in epithelial malignancies.
Nissan A
J Surg Oncol; 2007 Sep; 96(3):185-7. PubMed ID: 17443732
[No Abstract] [Full Text] [Related]
11. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of minimal residual disease in leukemia, advantages and pitfalls.
Cazzaniga G; Gaipa G; Rossi V; Biondi A
Ann Med; 2006; 38(7):512-21. PubMed ID: 17101542
[TBL] [Abstract][Full Text] [Related]
13. The detection and significance of minimal residual disease in acute and chronic leukemia.
Chung NG; Buxhofer-Ausch V; Radich JP
Tissue Antigens; 2006 Nov; 68(5):371-85. PubMed ID: 17092250
[TBL] [Abstract][Full Text] [Related]
14. Molecular diagnosis of hematopoietic and lymphoid neoplasms.
Jevremovic D; Viswanatha DS
Hematol Oncol Clin North Am; 2009 Aug; 23(4):903-33. PubMed ID: 19577174
[TBL] [Abstract][Full Text] [Related]
15. Minimal residual disease in hematological malignancies.
Raanani P; Hochhaus A
Acta Haematol; 2004; 112(1-2):5-7. PubMed ID: 15178998
[No Abstract] [Full Text] [Related]
16. Four-color flow cytometry detects minimal residual disease in leukemia.
Morrow T
Manag Care; 2006 Jan; 15(1):60-1. PubMed ID: 16502779
[No Abstract] [Full Text] [Related]
17. [Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation].
Hokland P; Nyvold CG; Stentoft J; Ommen HB; Ebbesen LH; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
Ugeskr Laeger; 2009 Jan; 171(4):229-31. PubMed ID: 19174037
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease (MRD) monitoring using rearrangement of T-cell receptor and immunoglobulin H gene in the treatment of adult acute lymphoblastic leukemia patients.
Toubai T; Tanaka J; Ota S; Fukuhara T; Hashino S; Kondo T; Kasai M; Kakinoki Y; Masauzi N; Morioka M; Kawamura T; Iwasaki H; Asaka M; Imamura M
Am J Hematol; 2005 Nov; 80(3):181-7. PubMed ID: 16247752
[TBL] [Abstract][Full Text] [Related]
20. Use of simplified strategies to evaluate early treatment response in childhood acute lymphoblastic leukemia.
Scrideli CA; de Paula Queiróz R; Bernardes JE; Defavery R; Valera ET; Tone LG
Leuk Res; 2006 Aug; 30(8):1049-52. PubMed ID: 16406015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
